MAKING ANTIBODIES IN BULK:
AT WHAT COST?
The HIV vaccine field is still in the midst of an antibody renaissance. Following the isolation of a handful of more broad and potent neutralizing antibodies five years ago, researchers have been busily studying these antibodies, identifying their targets on the virus, and using this information to advance the arduous task of designing vaccine immunogens capable of insuring such antibodies.
Meanwhile, these antibodies are also being pursued in other avenues of HIV prevention and treatment research. Should any of these efforts prove successful, the need to manufacture HIV monoclonal antibodies on an industrial scale may be necessary. But making these antibodies isn't cheap. Find out what is being done to improve antibody manufacturing and lower costs now, as well as what research was highlighted at the recent meeting of the HIV Vaccine Trials Network. Plus, a look at the staggering HIV rates among young, black men who have sex with men in the US. Read more...